Rhythm Pharmaceuticals (RYTM) Cash from Investing Activities (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has reported Cash from Investing Activities for 11 consecutive years, with $57.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 129.94% year-over-year to $57.1 million; the TTM figure through Mar 2026 stood at -$104.9 million (down 96.43% YoY), while the FY2025 annual figure was -$137.2 million, down 184.71% from the prior year.
• Cash from Investing Activities rose to $57.1 million in Q1 2026 per RYTM's latest filing, from $30.3 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $72.5 million in Q1 2022 and bottomed at -$246.3 million in Q3 2025.
• Historically, Cash from Investing Activities has averaged -$6.2 million across 5 years, with a median of $22.6 million in 2023.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities plunged 662.57% — and 2025, when it soared 731.1%.
• Rhythm Pharmaceuticals' Cash from Investing Activities stood at -$40.8 million in 2022, then surged by 155.52% to $22.6 million in 2023, then dropped by 6.55% to $21.2 million in 2024, then soared by 43.44% to $30.3 million in 2025, then surged by 88.0% to $57.1 million in 2026.
• Business Quant data shows RYTM's Cash from Investing Activities at $57.1 million in Q1 2026, $30.3 million in Q4 2025, and -$246.3 million in Q3 2025.